Shanghai Henlius Biotech
Works in Cardiovascular · Dermatology · ENT · GI & liver · Hematology · Immunology · Infectious disease · Metabolic & endocrine · Musculoskeletal · Neurology · Oncology · Ophthalmology · Renal & urogenital · Respiratory · Women's health
Shanghai Henlius Biotech is a clinical trial sponsor. It has 56 active clinical trials with 14,612 planned participants, across 15 therapeutic areas. Since 2021 it has completed 28 trials and stopped 6 early.
Trial track record · since 2021
Pipeline · 56 active trials
| Stage | Trial | Status |
|---|---|---|
On the market
2 approved drug applications with a product on the market.
Questions about Shanghai Henlius Biotech
Shanghai Henlius Biotech is lead sponsor of 56 active clinical trials on ClinicalTrials.gov, with 14,612 planned participants, in Cardiovascular, Dermatology, ENT, GI & liver and other areas. Since 2021 it has completed 28 trials and stopped 6 early.
From public sources only: ClinicalTrials.gov for trials, FDA's Data Dashboard, warning-letter listing and enforcement reports for the FDA record, and SEC filings for financials. Approve Suite is not affiliated with Shanghai Henlius Biotech; every record links to the source, and nothing here is advice.
See the rest of this profile
A free account shows the trial list, the financials and the fundraising filings. Pro adds a watchlist: one email when FDA acts on a company you name.
Trial counts are as the sponsor reported them to ClinicalTrials.gov, for trials changed since 2021; latest update 2026-10-13.
Approve Suite is not affiliated with Shanghai Henlius Biotech.
See something wrong on this page? Write to info@approvesuite.com and we will check it against the source. How corrections work.